(Reuters Health)—Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded. The risk of death from cardiovascular disease was 34% higher with febuxostat than with allopurinol. When researchers considered deaths from any cause, the risk was 22% higher…
Search results for: cardiovascular disease

The Why & What of the ACR’s Clinical Practice Guidelines
With the support of its membership, the ACR publishes clinical practice guidelines in multiple disease areas based on the best available clinical and scientific data. These aim to support health professionals treating rheumatology patients to give the best possible care. Like any set of medical guidelines, ACR guidelines are based on evidence of several different…

Managing Myositis in 3 Different Scenarios
SAN DIEGO—In Hot Topics in Myositis, a session held Nov. 7 at the 2017 ACR/ARHP Annual Meeting, rheumatologists discussed treating myositis patients in three different clinical scenarios: persistently elevated creatine kinase (CK), immune-mediated necrotizing myopathies and lung disease. Elevated CK Patients with persistently elevated levels of CK enzyme and normal muscle strength “may still have…

Can Rheumatologists Prescribe Exercise as Medicine?
SAN DIEGO—Exercise, within limits imposed by an individual’s circumstances, is an almost universally beneficial medical therapy. In fact, Teresa J. Brady, PhD, senior behavioral scientist with the federal Centers for Disease Control and Prevention’s Arthritis Program, labeled it “medicine” in a session on exercise at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. Dr. Brady asked whether…

The Diagnosis: How to Advise Newly Diagnosed RA Patients
Receiving an RA diagnosis may be emotional and difficult for patients. By engaging the patient in learning about the disease and its treatment options, as well as cultivating a communicative relationship, rheumatologists can truly help a patient take control of their health…

A History of the Science, Treatment of Rheumatologic Illnesses from Gold to Gene Therapy
Mysterious Ways The juxtaposition of the old and the new was readily evident that busy Wednesday morning. My first patient, a 94-year-old gentleman, Hal, arrived with a precise request. His rheumatologist for the past 40 years had just retired, and he was searching for a doctor with expertise in the use of gold sodium aurothioglucose,…

Year in Review: Expert Covers 2017’s Key Clinical Findings
In a Year in Review session at the 2017 ACR/ARHP Annual Meeting, Daniel Solomon, MD, MPH, highlighted the latest and most intriguing aspects of clinical research on rheumatic diseases from 2017. His discussion touched on medical therapy, genetics, the effects of bariatric surgery and diet, cancer risk and more…

Physical Activity, Exercise Can Benefit Patients with RA
While medical advances in rheumatoid arthritis (RA) have led to improvements in disease control and quality of life for patients worldwide, the rate for stable remission remains low.1 Management of RA symptoms is traditionally accomplished through a combination of medications and nonpharmacological interventions.2 This approach can prevent the development of secondary adverse health outcomes. Two…

The ACR Rheumatology Research Workshop Designed to Promote Collaboration, Mentoring Among Investigators
The ACR Rheumatology Research Workshop (RRW) is a two-day meeting designed to promote interactions between early and established investigators to foster collaboration and facilitate career mentoring. The RRW is targeted to rheumatology fellows, junior faculty, medical/graduate students, and residents interested in learning more about how to succeed in a research career for rheumatology. RRW is…
Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib
NEW YORK (Reuters Health)—Ibuprofen boosts blood pressure (BP) more than naproxen or celecoxib in patients who take non-steroidal anti-inflammatory drugs (NSAIDs) to treat arthritis, according to a new substudy from the PRECISION trial. “These drugs are different with regard to BP, and ibuprofen is the worst,” Dr. Frank Ruschitzka of University Hospital Zurich in Switzerland,…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 66
- Next Page »